Answers are grounded in this paper and cite their sources.
The effects of dose and renal function on the pharmacokinetics of mezlocillin were assessed in six normal volunteers and in ten chronic renal disease outpatients. Comparison was made to data from six functionally anephric patients given a 1 g dose during haemodialysis (HD). Each non-dialysed subject received a 1 and 5 g iv dose in a randomized cross-over manner. At both dosage levels serum concentrations declined biexponentially as a function of time. Dose- and time-average pharmacokinetic parameters revealed marked dose-dependence. Plasma clearance (Cl p ) and both renal (Cl r ) and nonrenal clearance (Cl nr ) were significantly decreased at the higher dose, with Cl nr exhibiting more marked dose-dependence than CI r . Both central ( Vc ) and steady-state ( Vss ) volumes of distribution were smaller at the higher dose. Volumes of distribution at the 1 g dose were similar to those of HD patients. Saturability of tissue uptake, of Cl r or of biliary clearance could partially explain the dose-dependent disposition. Cl p and Cl r correlated linearly with creatinine clearance (Cl cr ) at both dosage levels, but the 5 g: 1 g clearance ratios did not correlate with Cl cr . Cl nr at the 5 g dose was relatively unaffected (2.71/h/1.73 m 2 ) by varying Cl cr . However, at the 1 g dose, Cl nr decreased with decreasing Cl cr ; extrapolation of the regression line to a Cl cr of zero yielded a Cl nr approximately equal to that measured for HD patients. Dosing recommendations for mezlocillin should take into account the concomitant effects of dose and renal function on its pharmacokinetics.
No takes yet. Share an insight, caveat, or question.
Mangione et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: